TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

G. R. Oxnard, J. C.H. Yang, H. Yu, S. W. Kim, H. Saka, L. Horn, K. Goto, Y. Ohe, H. Mann, K. S. Thress, M. M. Frigault, K. Vishwanathan, D. Ghiorghiu, S. S. Ramalingam, M. J. Ahn

Research output: Contribution to journalArticlepeer-review

318 Citations (Scopus)

Fingerprint

Dive into the research topics of 'TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science